The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://tenor.com/en-GB/view/thumbs-up-success-doctor-house-dr-house-victory-gif-21867211
You wouldn’t believe we were getting some pre clinical date on AVA3996 in just a few days would you.
“The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company's second pre|CISION™ candidate, AVA3996,”
This article goes a long way to seriously (and in a quite shocking and depressing manner) dispelling the idea chemo is on the way out and vaccines are on the way in. What we need is a highly specific and easy to adjust type of monoclonal antibody mimic combined with chemo to constantly create new ways to battle cancer…. A catchy name like TMAC would fit such a treatment.
https://www.bbc.co.uk/news/health-65252510
Actually Kong Cohort 3 I believe took 6 weeks to complete. Cohort 4 took longer I believe because of a drop out/collating data. So I can see this Cohort taking 6 weeks so mid may, possibly sooner at this dose.
Again…. Which cancer? This is the exact same argument as the hundreds of drugs in trial. A vaccine for which one? They aren’t all the same. Who gets them? Does everyone get every vaccine for every cancer? Its as dumb a FUD as you get really. Covid has flu like symptoms. TB gives you an horrific cough. Can I take a cough vaccine that covers all 3?
I’ll put it simply…. You can’t give vaccines for absolutely everything to absolutely everyone. And what happens when you get cancer anyway? Is it like with covid where it’s bad but potentially not as bad as it could be? “Oh I’ve got mild cancer…… nothing to worry about”.
Anyway I’m of for my headache vaccine. All this stupid has made my head hurt.
100s of trials for cancer. Because cancer is just one single disease. Not a near endless array of varying types of disease defined by often very different characteristics, outcomes and treatments. Hundreds of trials there may be…. How many have low to no side effects at double the dose? We’re targeting a 1.5bn dollar per annum market with AVA6000 in a wider oncology market worth hundreds of billions per annum. The vast array of treatments needed is mind boggling and depressing with it.
On top of the above…. Pages 85 to 86 of the SD presentation that you didn’t look through.
There is huge potential for an improved next generation doxorubicin product considering:
• the market value being generated by current doxorubicin therapies and the expectation that doxorubicin- based therapies will continue to be a key approach for oncology treatment
• there is considerable scope for improvement on the profile of conventional and liposomal doxorubicin, around both safety / tolerability and efficacy
• there is modest future competitor activity exploring new doxorubicin approaches and few products identified to be in direct competition to AVA6000’s approach
So when you say hundreds what you actually mean is almost none.
It’s a real shame when facts smash your FUD right in the face.
Biopsies and STS in phase 1A. It’s like they’re trying to get as much data together as possible as early as possible for Alan’s next house purchase in the Bahamas when they sell the whole company before phase 1B even behinds.
I believe todays announcement is something they’d normally not bother telling us and let PIs find out somewhere themselves. Look at the positive effect comms has on the SP. It’s the point many of us here were hammering.